Oricell Therapeutics Appoints Dr. Feng Guo as Chief Executive Officer to Head Group Business and Operations

SHANGHAI, China, September 1, 2026 — Oricell Therapeutics Holdings Limited ("Oricell," "the Group" or "the Company"), a global leader in innovative cancer immunotherapy, announced the appointment of Dr. Feng Guo as Chief Executive Officer (CEO), with responsibility for the Group's overall business and operations. Dr. Huanfeng Yang, co-founder, Chairman and former CEO of Oricell, will continue to serve as Chairperson and President.

Dr. Huanfeng Yang, Co-founder, Chairperson and President of Oricell, said: "Dr. Guo brings more than 20 years of deep experience in the biopharmaceutical industry. He has led the clinical development and registration of multiple oncology drugs in China and driven the multicenter clinical expansion of related pipelines across the Asia-Pacific region. Before joining Oricell, Dr. Guo spent six years at a Hong Kong-listed biopharmaceutical company (Edding Genor, HKEX: 6998, formerly Genor Biotech), serving as CEO while also holding the roles of Executive Director and Chairman of the Board — with comprehensive, end-to-end experience spanning pipeline strategy, product commercialization, IPO and reverse takeover (RTO), and a rare combination of strategic resolve and execution. I am delighted that Dr. Guo chose to join Oricell from among many companies. Together, we will fully leverage the Company's deep technology platforms and differentiated product advantages, accelerate the clinical development of our clinical-stage products, expand international collaboration and capital markets resources, and propel the Company into a new phase of rapid growth."

Dr. Feng Guo, Chief Executive Officer of Oricell, said: "Oricell has established strong technological barriers and a rich product pipeline in cancer immunotherapy. The efficacy data from our lead product, Ori-C101, in advanced late-line hepatocellular carcinoma are remarkable: an objective response rate (ORR) of 66.7% in the recommended Phase 2 dose (RP2D) cohort, and a median overall survival (OS) of 21.4 months across all dose cohorts in the Phase I registration trial. I firmly believe in the broad prospects of cell therapies in oncology and immunotherapy. I truly appreciate this opportunity to join this outstanding team at this timepoint as the Company advances toward the capital markets and global expansion. Together with the team, I will dedicate myself to accelerating the clinical development of our core pipeline, strengthening international collaboration and capital

operations, and bringing our lead product to market — so that innovative, accessible CAR-T therapies can reach cancer patients around the world."

This appointment further consolidates the foundation of Oricell's international leadership team. The Company firmly believes that, as Ori-C101 advances through clinical development and its next-generation technology platforms continue to expand, a highly effective organization is the core driver of value creation. Going forward, Oricell will continue to attract top talent across disciplines and functions to meet the challenges of global competition, advance its long-term exploration in solid tumor therapy, and deliver on its commitment to patients through steady, substantive progress.

About Oricell Therapeutics

OriCell Therapeutics is a clinical-stage, globally oriented biotechnology company committed to pioneering cancer immunotherapy. Focused on addressing unmet medical needs in oncology and immunology, the company has built a robust pipeline spanning both solid and haematological tumours, powered by three proprietary technology engines: Ori®AB (AI-assisted antibody discovery and engineering), Ori®Armoring (structure-enhanced cell platform), and Ori®OnGo (classic, rapid, and in vivo manufacturing platform). The company's clinical translation capabilities have earned broad international recognition, with multiple data readouts selected for oral presentations at leading conferences including ASCO and EHA, and published in top-tier journals such as The Lancet Haematology. OriCell is accelerating its global expansion, driven by a commitment to continuous innovation and the ambition to bring new hope to cancer patients worldwide. For more information, please visit www.oricell.com.

Forward-Looking Statements

This press release contains forward-looking statements. These statements are not historical facts, but rather predictions about future events based on the beliefs, assumptions, and information currently available to the management of OriCell Therapeutics Holdings Limited (the "Company"). Words and phrases such as "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "plan," "potential," "predict," "project," "should," "target," "will," "would," and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements contain these

identifying words. Such statements involve known and unknown risks, uncertainties, and other important factors that could cause the Company's actual results, performance, or achievements to differ materially from those expressed or implied. Any forward-looking statements contained in this press release speak only as of the date of this release. The Company wishes to clarify that this announcement is intended solely to communicate research and clinical development progress, is for reference by healthcare professionals only, is not promotional in nature, and does not constitute a recommendation for the use of any unapproved drug or indication.

原启生物宣布任命郭峰博士为首席执行官

上海，2026 年 9 月 1 日 —— 全球创新肿瘤免疫疗法领军企业 Oricell Therapeutics Holdings Limited（以下简称"原启生物"，"本集团"或"Oricell"）今日宣布，任命郭峰博士为公司首席执行官（CEO），负责本集团整体业务及运营管理。原启生物联合创始人、董事长兼原首席执行官杨焕凤博士继续担任董事长兼总裁职务。

原启生物联合创始人、董事长兼总裁杨焕凤博士表示："郭峰博士在生物制药行业拥有超过 20 年的深厚经验，曾主导多款肿瘤药物在中国的临床开发与注册上市，并推动相关管线在亚太地区的多中心临床布局。加入原启之前，郭博士深耕港股生物制药上市公司（亿腾嘉和 HK6998，原嘉和生物）六载，担任首席执行官，期间兼任执行董事、及董事会主席多元身份，具备从研发管线布局、产品商业化到 IPO 及反向并购（RTO）的全周期实战经验，战略定力与执行力兼具。我非常高兴郭峰博士在众多的企业中选择加入原启生物，我们将一起努力，充分发挥原启生物积累的深厚技术平台能力和产品差异化优势，加快公司临床阶段的产品开发，拓展国际合作和资本市场资源，推动公司迈入高速发展新阶段。"

原启生物首席执行官郭峰博士表示："原启生物在肿瘤免疫治疗领域积累了深厚的技术壁垒和丰富的产品管线，尤其是核心产品 Ori-C101 在晚期末线肝细胞癌治疗中展现出的疗效数据令人振奋——RP2D 组 ORR 达 66.7%、I 期注册临床试验（所有剂量组）中位 OS 达 21.4 个月。我本人十分看好细胞治疗产品在肿瘤治疗以及免疫治疗领域的广阔前景。我也深感荣幸能在公司迈向资本市场和全球化发展的关键节点加入这支优秀的团队。我将与团队全力以赴，加速推进核心管线临床开发，加强国际合作与资本运营，推动核心产品早日实现商业化，让创新、可及的 CAR-T 产品惠及全球肿瘤患者。"

此次任命进一步夯实了原启生物国际化专业人才梯队建设基础。公司坚信，随着 Ori-C101 临床开发的纵深推进及下一代技术平台的持续拓展，高效的组织协同是价值创造的核心引擎。未来，公司将持续吸纳各路专才，以稳健应对全球竞争挑战，推动公司在实体瘤治疗领域的长期探索，以扎实的进展兑现对患者的承诺。

关于原启

原启生物是一家处于临床阶段的生物技术公司，致力于成为全球肿瘤免疫疗法领域的先锋开拓者。公司专注于开发创新型细胞疗法，以解决肿瘤学与免疫学中亟待满足的临床需求。依托自主构建的三大技术引擎——Ori®AB AI 抗体发现与工程平台）、Ori®Armoring（结构增强型细胞平台）及 Ori®OnGo（经典/快速/in vivo 工艺平台），原启生物系统性突破了实体瘤治疗的技术壁垒，并成功建立了涵盖实体瘤与血液瘤的丰富产品管线。公司的临床转化能力已获国际学术界高度认可：多项早期及注册临床试验验证了卓越的安全性与抗肿瘤活性，相关成果连续多次入选美国临床肿瘤学会（ASCO）、欧洲血液学协会（EHA）等国际顶尖学术会议口头报告，并发表于《柳叶刀·血液学》（Lancet Haematology）等权威期刊。公司开发的靶向 GPC-3 的 CAR-T 产品 Ori-C101 的注册临床 I 期研究数据优异，在 2026ASCO 学会年会进行口头报告，目前已启动 II 确证性临床试验，目前原启生物正加速推进全球化布局，致力于通过持续的技术创新，为全球肿瘤患者带来新的希望。欲了解更多信息，请访问公司官网：www.oricell.com